IFIH1 and dermatomyositis: For instance, the identification of MAs in patients with severe ILD has substantial implications for diagnosis and treatment, particularly in amyopathic dermatomyositis (DM) with anti-MDA5 autoantibodies and in cases of ASSD-associated anti-PL-7 or anti-PL-12 ARS autoantibodies [7,8].